Key Takeaways
- • Czech private equity firm ARX Equity Partners has acquired a majority stake in Slovenia's Medicofit (also referenced as Direct4me), a healthcare services provider, in partnership with healthcare investor Joseph Priel.
- • ARX, a CEE-focused private equity firm with more than €300 million raised across four funds, continues to build healthcare sector exposure in Central Europe following prior successful exits in the Slovenian diagnostics market.
- • The investment will support Medicofit's scaling and growth acceleration, though specific deal valuation and transaction size have not been disclosed in available sources.
- • ARX's track record in Slovenian healthcare includes a prior DCB acquisition (2015) that generated a 3.6x cash-on-cash return and internal rate of return exceeding 25%, demonstrating the firm's operational execution capability in the region.
Summary
ARX Equity Partners, a Prague-based private equity firm focused on the Central European region, has completed the acquisition of a majority stake in Medicofit, a Slovenian healthcare services provider. The transaction marks ARX's continued strategic focus on healthcare consolidation in Southeast Europe, executed in partnership with healthcare sector investor Joseph Priel.
ARX has established itself as a leading mid-market private equity operator in Central Europe, having raised more than €300 million across four dedicated funds. The firm's investment thesis in the Slovenian healthcare market is supported by prior operational success: ARX acquired DCB, a diagnostics business, in 2015 and subsequently exited the position, achieving a 3.6x cash-on-cash multiple and an internal rate of return exceeding 25%. This track record demonstrates the firm's ability to identify, acquire, and build healthcare platforms in the region.
The Medicofit investment will be deployed to accelerate the scaling of the company's operations and support its near-term growth trajectory. While specific transaction valuation and deal economics have not been disclosed, the investment represents ARX's ongoing capital deployment strategy within its healthcare vertical across the CEE region. The partnership with Joseph Priel, an established healthcare investor, suggests sector-specific operational expertise will be brought to bear on value creation initiatives.
The transaction underscores continued private equity activity in Southeast European healthcare services, where consolidation opportunities and scalable platform businesses remain attractive to mid-market sponsors seeking geographic diversification and sector-specific returns outside Western European markets.
ARX has established itself as a leading mid-market private equity operator in Central Europe, having raised more than €300 million across four dedicated funds. The firm's investment thesis in the Slovenian healthcare market is supported by prior operational success: ARX acquired DCB, a diagnostics business, in 2015 and subsequently exited the position, achieving a 3.6x cash-on-cash multiple and an internal rate of return exceeding 25%. This track record demonstrates the firm's ability to identify, acquire, and build healthcare platforms in the region.
The Medicofit investment will be deployed to accelerate the scaling of the company's operations and support its near-term growth trajectory. While specific transaction valuation and deal economics have not been disclosed, the investment represents ARX's ongoing capital deployment strategy within its healthcare vertical across the CEE region. The partnership with Joseph Priel, an established healthcare investor, suggests sector-specific operational expertise will be brought to bear on value creation initiatives.
The transaction underscores continued private equity activity in Southeast European healthcare services, where consolidation opportunities and scalable platform businesses remain attractive to mid-market sponsors seeking geographic diversification and sector-specific returns outside Western European markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.